ChroMedX Collaborates With Microfluidic And Microfabrication Experts For HemoPalm Cartridge Development

Toronto, Ontario
March 23, 2015

ChroMedX Corp. (the “Company”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce it has entered into a collaboration with Dr. Ravi Selvaganapathy of McMaster University to assist in the design and development of prototype cartridges for the Company’s patented HemoPalm blood analyzer system.

The McMaster and ChroMedX partnership has been awarded an NSERC Engage Grant which is funded by NSERC (Natural Sciences and Engineering Research Council of Canada).

Dr. Selvaganapathy is Associate Professor in the Department of Mechanical Engineering and Canada Research Chair in Biomicrofluidics and is an expert in microfluidics and microfabrication.  The project also involves Dr. Tauhiduzzaman who is a Postdoctoral Fellow in the McMaster Manufacturing Research Institute (MMRI) with expertise in microfabrication.  The design will be prototyped in McMaster’s Machine Systems Laboratory which is part of the McMaster Manufacturing Research Institute (MMRI) overseen by Dr. Stephen Veldhuis.  It is expected that the first designs will be prototyped and tested within the next 30-60 days.

“We are very pleased with the addition of expertise in microfluidics and microfabrication through this grant that greatly complements our initiative and will provide the flexibility necessary to be successful at this stage of cartridge development.  Micromachining will not only allow us to examine the various mechanical and fluidic aspects of the cartridge including activation of the calibration fluid pouch, but will also allow us to evaluate the cartridge performance during development of calibration algorithms for CO-oximetry (spectroscopic measurement of 5 hemoglobin species).  Micromachining can create prototypes more quickly and at significantly lower cost compared to injection moulding, which is preferred for manufacturing the final product.  Therefore design changes can be implemented in a less expensive and rapid fashion.”

The cartridge will utilize a calibration fluid pouch provided by vendor ThinXXS of Zweibruken, Germany.   Testing of previous versions of the pouch allowed one with superior stability to be selected.

The Company recently announced the addition of biosensor expert Mr. Steve Cozzette to the development team focusing on electrochemical sensor and cartridge development aspects of the HemoPalm platform.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing.  The devices are protected by the Company’s issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:


Investor Enquiries:

W. Clark Kent


Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law.   Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur.   Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE.   There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control.   The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law.   The reader is cautioned not to place undue reliance on forward-looking statements.   Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at